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related to diagnosis, we first considered the qual-
ity of evidence (representing our confidence that 
an estimate of the effect of a testing strategy on 
patient outcome is sufficient to support a partic-
ular recommendation). Eligible studies included 
both those addressing diagnostic accuracy (cross-
-sectional accuracy studies) and studies examining 
the consequences of particular diagnostic strate-
gies (prospective management studies). We con-
sidered both accuracy and management studies as 
providing high quality of evidence, unless down-
graded by the following factors – limitation of de-
sign and execution (e.g., unrepresentative patients, 
lack of independent assessment of test and criteri-
on standard), inconsistency (differences between 
the results), indirectness with respect to the popu-
lation studied, the tests performed or the outcome 
measured, lack of sufficient precision and risk of 
publication bias. We used the following categories 
for the quality of evidence: high (A), moderate (B), 
low (C), and very low (D). We graded the strength 
of recommendations as “strong” (1) or “weak” (2) 
depending on the degree of our confidence that 
following recommended course of action will lead 
to optimal patient outcomes. When recommenda-
tions are strong we use the wording “we recom-
mend”; when recommendations are weak, we use 
the wording “we suggest”.
REsuLTs Our search yielded a number of rele-
vant practice guidelines5-10 and meta-analyses11-15. 
Tables 2–5 (Appendix A) summarize the evidence 
from those sources. Below we present the recom-
mendations our panel developed on the basis of 
the evidence.
§1. Recommendations Clarifications Under-
standing these recommendations requires knowl-
edge of the following:
1 Our recommendations rely on pre-test prob-
ability (pre-TP) estimates generated by validated 
clinical prediction rules.11
2 When, following testing, the probability of 
DVT is <2%, we recommend (or suggest, depend-
ing on the precision of estimates of probability) 
clinical follow-up alone; if the probability of DVT 
is ≥2%, we recommend or suggest further test-
ing. The threshold of 2% represents the consen-
sus of the authors.
3 Although we did not formally model the im-
pact of alternative strategies on the key outcomes 
of death and disability from venous thrombosis 
and bleeding, our threshold of 2% for the proba-
bility of DVT, and our requirement for a positive 
proximal leg US for diagnosis, minimizes the like-
lihood of adverse outcomes of either thrombosis 
or bleeding. On the other hand, this low thresh-
old places a low value on avoiding additional di-
agnostic testing. Those who place a higher value 
on avoiding diagnostic testing, and a lower val-
ue on avoiding thrombosis or bleeding, would 
choose a higher threshold.
INTROduCTION The ultimate goal of choosing 
one management strategy over another is to im-
prove outcomes that patients find important. For 
a variety of reasons, diagnostic tests may be ac-
curate but fail to improve such outcomes.1 Thus, 
clinical practice guideline panels should base judg-
ments of the quality of evidence and recommen-
dations for diagnostic tests not solely on accu-
racy, but must consider the likelihood of patient 
benefit.
Providing a structure for guideline panels to 
consider quality of evidence and strength of rec-
ommendations for diagnostic tests based on im-
pact on patient-important outcomes is a chal-
lenging task. Recently, the GRADE working group 
has provided such a structure.2,3 In this paper, 
we test the feasibility and performance of the 
GRADE approach by applying this framework to 
well-researched issues in the diagnoses of deep 
venous thrombosis (DVT).
Prompt diagnosis of DVT is important to pre-
vent pulmonary embolism (PE) which can be rap-
idly fatal. Diagnosing DVT when it is not present 
places patients at increased risk for bleeding as a 
result of anticoagulation. Thus, achieving optimal 
patient outcomes requires an accurate, prompt 
diagnosis of DVT.
Clinicians use three categories of information 
to determine the probability of DVT: 
1 clinical prediction rules based on the patient’s 
history and clinical presentation 
2 results of D-dimer test 
3 results of radio logical tests, most commonly 
compression venous ultrasound (CUS), much less 
frequently venography, and even less frequently 
magnetic resonance imaging.
This paper provides evidence-based clinical 
practice guidelines (CPG) focusing on the diag-
nosis of first episode of DVT in the ambulatory 
setting (outpatient or emergency room, i.e., not 
among hospitalized patients) using the GRADE 
framework. We do not address issues pertaining to 
the specific diagnosis of PE, recurrent DVT, upper 
extremity DVT, and pregnancy-associated DVT.
METhOds development of recommendations 
A group of individuals with an inter est in venous 
thromboemblism (VTE) and practice guidelines 
development methodology identified questions 
pertaining to the diagnosis of DVT (for eligibili-
ty criteria see Table 1, Appendix A). We searched 
for evidence addressing these questions by ex-
amining studies cited in related CPG and meta- 
-analyses identified by reviewing the National 
Guideline Clearinghouse4, the National Library 
of Medicine (PubMed), the Cochrane Library, CI-
NAHL and EMBASE (using search terms: ultra-
sonography, D-dimer, DVT, specificity, systemat-
ic). We developed recommendations on the ba-
sis of this evidence.
Assessing quality of evidence and strength of recom-
mendations Following the approach articulated 
by GRADE for formulation of recommendations 
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R4. In patients with a high pre-TP for DVT we 
recommend CUS as an initial test over other ini-
tial strategies (empiric treatment, venography, 
D-dimer) (1B). We further recommend treatment 
if the initial CUS is positive (1A) and suggest re-
peat CUS over performing D-dimer during initial 
visit if the first CUS is negative (2B) (Tables 2–4, 
§2.3, §2.6, §2.7).
Recommendations R5–R8 assume use of moderate-
ly sensitive d-dimer test (sensitivity approximate-
ly 85%, FIGuRE 2)
R5. In patients with a low pre-TP, we recom-
mend D-dimer with clinical follow-up if negative, 
and CUS if positive, over CUS in all (1A) (Tables 
2–3, §2.3, §2.9).
R6. In patients with a low pre-TP, positive D-dimer, 
and negative CUS we suggest repeat CUS over clin-
ical follow-up alone (2B) (Table 5, §2.8).
R7. In patients with a moderate pre-TP for DVT, 
we recommend CUS over other initial strategies 
(empiric treatment, venography, D-dimer) (1A). 
We recommend treatment if CUS is positive (1A). 
In patients with negative CUS, we recommend D-
dimer during initial visit over repeat CUS, with 
repeat CUS if D-dimer is positive and clinical fol-






R8. In patients with a high pre-TP for DVT, we 
recommend CUS over other initial strategies (em-
piric treatment, venography, D-dimer) (1A) and 
we recommend treatment if CUS is positive (1A). 
In those patients with negative CUS we suggest 
repeat CUS over performing D-dimer during ini-
tial visit (2B) (Tables 2–4, §2.3, §2.6, §2.7). 
4 Because D-dimer tests vary in accuracy, clini-
cians using these guidelines need to be familiar 
with the product they are using.
5 Our recommendations assume that CUS ex-
amines the proximal veins of lower extremity 
(common femoral, femoral and popliteal, often 
including the most proximal portions of the per-
oneal and tibial veins).
6 Our recommendations to repeat CUS refer to 
repeat testing in 5–7 days.
7 Evidence suggests that the accuracy of CUS, 
duplex US and triplex US are essentially equiva-
lent15 and CUS is less expensive; therefore, all rec-
ommendations refer to the use of CUS.
8 By clinical follow-up we mean subsequent 
monitoring according to clinician judgment with 
no obligatory testing.
9 Review of Tables 2–5 will clarify the rationale 
for our recommendations.
We subsequently expand on some of the above 
statements.
Recommendations R1–R4 below assume use of high-
ly sensitive d-dimer test (sensitivity approximate-
ly 95%, FIGuRE 1)
R1. In patients with a low or moderate pre-TP, 
we recommend D-dimer as the initial test with 
clinical follow-up if negative, and CUS of the prox-
imal veins if positive, over initial testing with CUS 
(1A) (Tables 2–3, §2.3, §2.9).
R2. In patients with a low pre-TP, positive 
D-dimer and negative CUS, we suggest repeat 
CUS over clinical follow-up without repeat CUS or 
CUS of the distal veins (2B) (Table 5, §2.8).
R3. In patients with a moderate pre-TP, posi-
tive D-dimer, and a negative CUS we recommend 


































§2. Further rationale for recommendations
2.1. Our recommendations rely on pre-TP estimates 
generated by clinical prediction rules All our rec-
ommendations require an estimate of pre-TP. All 
studies that provided the evidence on which we 
rely used clinical prediction rules (e.g., those de-
veloped by Wells et al., Appendix B) to estimate 
pre-TP of VTE. The rules are based on combina-
tions of clinical assessment of risk factors and 
physical findings – individual clinical features are 
poorly predictive. The prevalence of DVT in cate-
gories of pre-TP varies considerably across stud-
ies: in the original study by Wells et al. those prob-
abilities were 3, 17, and 75% for low, moderate, 
and high pre-TP, respectively.16 In the review by 
Tamariz et al. the observed range of probabilities 
was 0–13% for low pre-TP, 0–38% for moderate 
pre-TP, and 17–85% for high pre-TP.11 Whether 
the results in Tables 2–5 also apply to other ap-
proaches to generating pre-TP (e.g., clinical judg-
ment) is uncertain. Some clinical situations may 
increase the probability of DVT regardless of pre-
diction rules score (e.g., presence of vena cava fil-
ter or concurrent symptoms consistent with pul-
monary embolism).
2.2. Our recommendations assume that a post-TP of 
<2% is required in order to recommend or suggest 
clinical follow-up rather than further tests Diag-
nostic strategies for DVT often seek to reduce the 
probability of DVT to a level that justifies clini-
cal follow-up rather than repeat testing. Since we 
cannot reduce the probability to ≤1% (even nor-
mal results of venography leave a probability of 
VTE of up to approximately 1–2%)17, we use a 
threshold of 2% for further investigation vs. clin-
ical follow-up alone. That is, if after applying a di-
agnostic strategy the probability of DVT is great-
er than 2%, we recommend or suggest additional 
 Recommendations R9–R13 below assume d-dimer 
tests described above are not available (FIGuRE 3)
R9. In patients with suspected DVT, we recom-
mend CUS of the proximal veins over other strat-
egies as an initial test (1A) (Table 3, §2.6).
R10. In patients with a low pre-TP for DVT and 
negative CUS, we recommend clinical follow-up 
over further testing (1A) (Table 3, §2.6).
R11. In patients with low pre-TP and posi-
tive CUS, we suggest treatment with no further 
testing over venography to confirm DVT (2A) 






R12. In patients with a moderate-to-high pre-TP 
for DVT and positive CUS, we recommend treat-
ment over further testing (1A) (Table 3, §2.6).
R13. In patients with a moderate-to-high 
pre-TP for DVT and negative CUS, we recom-
mend repeat CUS over clinical follow-up (1B) 
(Table 3, §2.6, §2.7).
Other recommendations not related to d-dimer 
availability
R14. In patients with suspected DVT who have 
an equivocal or inadequate CUS we recommend 
prompt repeat CUS or venography over long-term 




R15. In patients with moderate or high pre-TP, 
when diagnostic tests are delayed we recommend 
treatment until tests are available over no treat-
ment (1A); in such patients with a low pre-TP, we 
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patients with a low pre-TP were associated with 
a 3-month probability of VTE of 0.5% (95% CI 
0.07–1.1%; Table 2; R5); moderate sensitivity tests 
can therefore effectively rule out DVT in such pa-
tients. On the other hand, the incidence of DVT 
was 3.5% and 21.4% in those with a moderate 
or high pre-TP and a negative test, respective-
ly, thus precluding initial use of the moderately 
sensitive D-dimer to exclude DVT in this popu-
lation (R7, R8).12
Aside from the highly and moderately sensitive 
D-dimer assays about which we make recommen-
dations, there are also low sensitivity D-dimer 
tests available. These tests are, however, used in 
investigations of disseminated intravascular co-
agulation. Again, we emphasize that clinicians 
should be aware of which test they are ordering.
Another reservation about D-dimer relates to 
the timing of presentation and use of anticoag-
ulants. The sensitivity of D-dimer test is reduced 
if the duration of symptoms or signs exceeds 2 
or 3 days prior to the test or with the use of hep-
arin before testing.10
Lastly, specificity of all available D-dimer as-
says is too low to allow use of those tests to con-
firm presence of VTE, hence further diagnostic 
tests are required (R1–R8).
Appendix C presents the performance char-
acteristics of different D-dimer tests in more 
detail.
2.4. Our recommendations assume that Cus exam-
ines the proximal veins of lower extremity (popliteal, 
superficial femoral, and common femoral) Two 
considerations support this approach. First, the 
accuracy of CUS to detect DVT below the popliteal 
vein is inconsistent and appears to be highly oper-
ator dependent. Second, the significance of clots 
in the calf is uncertain (whether, for instance, 
they cause PE and how often they do so).18
2.5. Our recommendations to repeat Cus includes 
a time frame of 5–7 days When we refer to re-
peat CUS, we assume a time frame of 5–7 days for 
testing. If the probability is less than 2% we rec-
ommend or suggest clinical follow-up with ad-
ditional testing if new or progressive symptoms 
occur. When the confidence inter val around the 
point estimate of the probability of DVT crossed 
the 2% threshold, we rated quality down for im-
precision. Tables 2–5 provide the necessary infor-
mation to choose an appropriate course of action 
for different thresholds. The threshold is likely to 
differ across patients, and this is reflected in the 
strength of our recommendations. 
2.3. different d-dimer tests have different charac-
teristics (and thus require differing recommenda-
tions for use) There exist a variety of D-dimer 
assays with different test properties. Authors 
of a systematic review of rapid D-dimer assays 
(their rapidity making them suitable for outpa-
tient use) report summary estimates of high-
ly sensitive D-dimer assay sensitivity as 97.7% 
(95% CI 96.1–99.0%) and specificity of 45.7% 
(95% CI 28–66.6%) with a likelihood ratio (LR) 
for a negative test result of 0.05.12 Another sys-
tematic review found similar estimates of sensi-
tivity (~95%) among assays collectively labeled 
as highly sensitive D-dimer tests (ELISA, rapid 
ELISA, immunoturbidimetry).13
Authors of the systematic review summarizing 
results of management studies of rapid D-dimer 
based diagnostic strategies concluded that the 
negative result of a highly sensitive D-dimer test 
indicated less than 0.5% 3-month probability of 
VTE among outpatients with low-to-moderate 
pre-TP (but over 6% probability among patients 
with high pre-TP; Table 2; R1, R4).12
In contrast, the summary estimate of sensitivi-
ty of the moderately sensitive SimpliRed D-dimer 
test (also referred to as whole blood, qualitative 
hemagglutination assay) is 87.5% (95% CI 82.4–
91.7%), and the summary estimate of specificity 
is 76.9% (95% CI 65.4–86.2%) with the LR for a 
negative test result 0.16.12 In management stud-
ies the negative results of the most studied rap-


























CUS the 3-month prevalence of DVT is 2–4%.17 
In such patients, the addition of negative D-dim-
er lowers the probability to <1% (details below). 
Such a study, however, was not performed among 
only high pre-TP patients.
In one cohort study (overall prevalence of DVT 
22%), 828 patients with a negative initial CUS 
followed by a negative D-dimer test (moderately 
sensitive) had a DVT prevalence of 0.7% (95 % 
CI 0.3–1.6%).19 In another cohort study involv-
ing 531 patients with a moderate-to-high pre-TP 
(65% of whom had positive initial CUS), 148 pa-
tients with a normal CUS and normal D-dimer 
test (moderately sensitive) had a DVT prevalence 
of 0% (95% CI 0–3%).20 In a third study involv-
ing 495 patients (overall prevalence of DVT 27%), 
none of 81 patients with moderate-to-high pre-TP, 
negative D-dimer and negative CUS had VTE dur-
ing a 3-month follow-up.21 Similar results were 
observed in the last of the four cohort studies in 
which the overall incidence of DVT was ~28% and 
DVT occurred in 3 out of 598 people with nega-
tive CUS followed by a negative D-dimer.22
This strategy of using a moderately sensitive 
D-dimer (SimpliRed) was also tested and shown 
equivalent to repeat venous US in a randomized 
study by Kearon23 (overall prevalence of DVT 
was, however, below 10%). In this study, 810 pa-
tients with a negative initial CUS were random-
ized either to repeat CUS, or to D-dimer test-
ing followed, if D-dimer positive, by venogra-
phy. Among 309 patients with a negative initial 
CUS and negative D-dimer 3 (1%, 95% CI 0.2–
2.8%) developed VTE during 6 months of follow-
up. We have pooled available cohort studies us-
ing fixed effect model with resulting post-TP of 
0.6% (95% CI 0.3–1.1%), with inclusion of RCT 
0.7% (95%CI 0.4–1.2%) (Table 4; R4, R7, R8). To 
decide on our panel preference between CUS re-
peated 5-7 days later and D-dimer done imme-
diately following first negative CUS we used the 
GRADE grid, a formal process to resolve differ-
ences of opinions.24 This approach led us to dif-
ferent recommendations depending on the pre-
TP: for patients with high pre-TP we suggest re-
peat CUS and for those with moderate pre-TP we 
recommend D-dimer (R4, R7, R8).
If D-dimer is not available, repeat CUS is our 
preferred option in such patients (R13). If first 
CUS is inconclusive or inadequate, venography 
may be considered (R14). The choice of venog-
raphy may depend on the technical and clinical 
skills available in a given health care setting, and 
clinical circumstances and preferences of indi-
vidual patients.
2.8. Management strategies following positive 
d-dimer and negative Cus Patients with mod-
erate-to-high pre-TP of DVT and positive D-di-
mer may have over 10% probability of VTE de-
spite a negative first CUS.20 The relevant study 
did not separate moderate and high pre-TP pa-
tients. Those with moderate pre-TP, a positive 
D-dimer, and a negative initial CUS are likely to 
repeat testing.15 When we refer to “clinical follow-
up”, we imply no additional testing towards DVT 
unless new or progressive symptoms occur.
2.6. Our recommendations assume use of Cus 
as a preferred radio logical test Contrast venogra-
phy remains the definitive test to rule out the di-
agnosis of DVT. It has, however, numerous draw-
backs including resource use, technical challeng-
es, discomfort to the patient, limited availability, 
risk of adverse effects from IV contrast, and sec-
ondary thrombosis. For these reasons, venogra-
phy is generally reserved for research studies and 
for highly selected patients who pose a diagnos-
tic dilemma (R14).
The sensitivity of CUS is approximately 95% for 
the diagnosis of symptomatic proximal lower ex-
tremity DVT (Table 3; R1–15).8,9,15 The sensitiv-
ities of different modes of US differ only slight-
ly (93–96%)15 and such differences are unlikely 
to be of clinical significance: sensitivities for de-
tection of proximal DVT from 93.8 for CUS (95% 
CI 92–95.3%) to 96.5% for duplex US (95% CI 
95.1–97.6%). Specificity of CUS is 97.8% (95% 
CI 97–98.4%), numerically slightly higher than 
for duplex (94%; 95% CI 92.8–95.1%) or triplex 
US (94.3%, 95% CI 92.5–95.8%).
According to a review of US performance15, lim-
itations of US sensitivity do not translate into 
high rates of adverse outcomes. This is probably 
due to repeated testing in a population of higher 
pre-TP (or those with a positive D-dimer), high 
negative predictive value when a reasonably sen-
sitive test is applied to a population with low dis-
ease prevalence, and finally, because DVT that is 
not detected by US may have a relatively benign 
natural history.
Considering all of the above, a single nega-
tive US does not rule out DVT with sufficient 
certainty in patients with moderate or high pre-
TP of DVT, where the prevalence of DVT among 
such patients may be up to 4% (Table 3; R3, R4, 
R7, R8, R13).15,17
CUS is an operator-dependent procedure. All 
our recommendations assume that CUS in indi-
vidual institutions retains the measurement prop-
erties demonstrated in the published studies. An-
ecdotal experience suggests this is not always the 
case. To the extent that CUS in some hospitals 
is less accurate, the evidentiary basis for our rec-
ommendations is indirect (and the quality of ev-
idence should be downgraded for indirectness). 
Despite this uncertainty, we have chosen not to 
downgrade for indirectness.
2.7. Management strategies following negative 
Cus result in patients with moderate or high pre-
TP Following a first negative CUS (conducted 
as the initial test) in patients with a moderate 
or high pre-TP for DVT, an acceptable diagnostic 
strategy may include subsequent moderately sen-
sitive or highly sensitive D-dimer performed at 
the time of initial presentation. Among patients 
with moderate to high pre-TP and negative initial 
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different health care systems with different access 
to specific diagnostic tests (in this case, D-dimer 
assays) we provided three diagnostic algorithms 
(based on use of highly sensitive and moderately 
sensitive D-dimer, or no use of D-dimer).
Our recommendations and suggestions are, in 
general, similar to those of other available guide-
lines and review papers.8,10,28 Important differenc-
es from some, but not all, other guidelines include 
our recommendation to perform the highly sensi-
tive D-dimer assay as an initial test not only in pa-
tients with low but also moderate pre-TP of DVT, 
and to conduct only clinical follow-up in those 
with negative results. In some other cases we pro-
vide the rationale for and potential for alternative 
management strategies in areas where desirable 
and alternative consequences of alternative cours-
es of action are unclear or closely balanced. This 
is true, for example, of our recommendations to 
perform either moderately or highly sensitive D-
dimer test at the initial presentation in patients 
with moderate pre-TP following negative initial 
CUS, as opposed to repeating the CUS few days 
later. It is also true of our recommendation that 
in patients with high pre-TP clinicians repeat CUS 
5-7 days later as opposed to performing D-dimer 
test at the original presentation.
The diagnostic reasoning in DVT is tradition-
ally based on the ability of different diagnostic 
strategies to rule out the disease. None of these 
strategies is perfect. Even the reference standard 
– venography – may be associated with up to 2% 
of false negative rate (up to 20/1000 people with 
negative venogram may have proven DVT within 
3 months clinical follow up time). Performance 
of CUS or D-dimer test alone is associated with 
more false negative results.
Deciding on the level of post-TP at which one 
may choose clinical follow-up alone over further 
testing is a subjective one, based not only on the 
available evidence, but also on the underlying val-
ues and preferences associated with the conse-
quences of misdiagnosis (either missed DVT or 
unnecessary treatment) and resource use. Our 
guidelines are based on a threshold of 2%. Pa-
tients’ thresholds are likely to differ, and to the 
extent this is the case our recommendations may 
not apply. Patients with a lower threshold will al-
most always prefer subsequent testing to clinical 
follow-up; those with a higher threshold might 
on occasion prefer clinical follow-up rather than 
the additional testing we suggest.
The approach we have taken does have limita-
tions. Rather than identifying and examining in-
dividual studies ourselves, we have collected and 
summarized evidence from meta-analyses pro-
duced by other authors. The evidence summa-
rized in these meta-analyses is several years old, 
and the meta-analyses did not use the most re-
cent methods for arriving at summary estimates. 
This represents a weakness of our guideline.
A second limitation is that we did not calcu-
late the number of bleeding events that would 
occur with different diagnostic thresholds and 
have a DVT prevalence lower than observed 18%, 
but probably not below the threshold allowing no 
further testing (Table 5; R3).
The optimal management patients with low 
pre-TP of DVT, positive D-dimer, and subsequent 
negative CUS performed at initial presentation is 
not clear. The prevalence of DVT among patients 
with negative CUS followed by positive D-dimer 
may be as high as 6%.22 This estimate, however, 
was obtained in a population with an initial prev-
alence of DVT over 20%. In a study including 896 
patients with unequivocally low pre-TP, among 
280 patients with negative initial CUS and pos-
itive D-dimer, 7 (2.5%) had DVT detected on re-
peated screening CUS done because of positive D-
dimer (there may have been other patients with 
symptomatic DVT in this subgroup – this is not 
clear from the report).19 In the previously quot-
ed study by Wells et al, none of the 85 patients 
with positive D-dimer and negative CUS devel-
oped VTE during follow-up.21 In another study, 
calf vein DVT was detected by repeat CUS in 2 out 
of 113 (1.8%) patients with positive D-dimer and 
originally negative CUS.25 Although this frequen-
cy and location of clots may be insufficient to war-
rant repeated CUS, our suggestion is to perform 
follow-up CUS (2B) (Table 5; R2, R6).
2.9. Our recommendations are intended exclusively 
for ambulatory out-patients presenting with symp-
toms associated with first episode of dvT Most 
studies were done in ambulatory care setting and 
involved patients with recent onset of symptoms 
who are not receiving anticoagulation therapy.26 
The applicability of these studies’ findings to other 
settings (including hospitalized patients) is lim-
ited, and our recommendations are not intend-
ed for such patients.
Patients with recent major trauma or surgery 
and those with cancer or pregnancy may have in-
creased plasma D-dimer levels that will decrease 
the specificity and predictive value of the pos-
itive D-dimer test. Such results may also occur 
in common conditions that can present in a way 
similar as DVT - cellulitis, hematoma, musculo-
skeletal injury, inflammatory arthritis. The util-
ity of D-dimer may be also decreased in very el-
derly in whom the specificity of D-dimer is low-
er than in other populations.27 At the same time, 
as the sensitivity is not decreased, the useful-
ness of negative test results in ruling out dis-
ease is maintained.
dIsCussION Our goal in writing this manuscript 
was to utilize an explicit and transparent meth-
odology to provide a set of clinically relevant and 
comprehensive recommendations that clinicians 
can apply to patients with suspected lower limb 
DVT. In our preliminary work, we have found a 
number of CPGs in this area. Our CPG differs from 
those found in two ways. First, we have used the 
GRADE approach to judge both quality of evidence 
and strength of recommendations. Second, as our 
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formally include these in a trade off with throm-
botic events, inconvenience and cost of anti-
thrombotic therapy, and inconvenience and cost 
of testing. This is also true for our recommen-
dation in favor of US rather than venography as 
the definitive diagnostic test. Future iterations of 
these guidelines would be strengthened by mak-
ing such calculations and formal tradeoffs.
Our use of the GRADE system has mandated 
explicit evidence summaries, ratings of the qual-
ity of evidence, consideration of indirectness in 
rating quality of evidence, and specifying recom-
mendations as strong or weak. Our explicit pre-
sentations of the evidence supporting our judg-
ments in the tables and in the text, and our ex-
plicit statements regarding issues such as our 
diagnostic threshold, will facilitate constructive 
debate and help others to be transparent and ex-
plicit in making their own judgments.
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wsTęP  System GRADE zaproponował podejście do  tworzenia wytycznych praktyki klinicznej  (cli-







METOdy Po sformułowaniu pytań klinicznych przeszukaliśmy  literaturę z uwzględnieniem  istnieją-
cych CPG i przeglądów systematycznych. Wyniki podsumowaliśmy w postaci tabel (pro fili danych) 
formułując na ich podstawie zalecenia.
wyNIKI I wNIOsKI  Przedstawiamy trzy grupy zaleceń dla lekarzy praktykujących w warunkach z dostępem do róż-
nego rodzaju oznaczeń dimeru D (DD), tj. testów o dużej lub umiarkowanej czułości, i w warunkach bez możliwości 
oznaczenia DD. Uwzględniamy zastosowanie oceny prawdo podobieństwa klinicznego w ukierunkowaniu procesu 
diagnostycznego, możliwość wykluczenia DVT przy ujemnym wyniku oznaczenia DD lub ultrasonograficznego 
testu uciskowego (compression ultrasound – CUS) oraz znaczenie kolejnych badań diagnostycznych po wyko-
naniu badań wstępnych (zastosowanie CUS w przypadku dodatniego wyniku oznaczenia DD, oznaczenie DD 
po uzyskaniu ujemnego wyniku CUS i powtórne wykonywanie CUS), w zależności od prawdo podobieństwa DVT 
na początku procesu diagnostycznego. Zalecamy następujące postępowanie: jeżeli oznaczenie DD testem o dużej 
lub umiarkowanej czułości nie jest możliwe, rozpoznanie DVT należy oprzeć na wyniku CUS; jeżeli oznaczenie 
DD jest możliwe, u pacjentów z małym lub pośrednim prawdopodobieństwem DVT (ocenionym za pomocą skali 
Wellsa) należy oznaczyć DD testem o dużej czułości, w celu określenia czy konieczne jest wykonanie CUS; pacjen-
tów z małym wyjściowym prawdopodobieństwem DVT i ujemnym wynikiem oznaczenia DD za pomocą testu o 
dużej lub umiarkowanej czułości należy jedynie obserwować, bez wykonywania dalszych badań diagnostycznych; 
aby u pacjentów z dużym wyjściowym prawdopodobieństwem DVT wykonywać CUS bez oznaczania DD.
sŁOwA KLuCZOwE
GRADE, rozpoznanie, 
wytyczne praktyki 
klinicznej, zakrzepica 
żył głębokich
